

APO.V (Acasti Pharma Inc.) CDNX
17-Oct-2011 11:09 am

© StockCharts.com



A background image showing a row of five clear glass test tubes. A red pipette is positioned above the second tube from the left, with a single drop of red liquid about to fall into it. The scene is brightly lit, creating soft shadows and highlights on the glass surfaces.

Investor's presentation
The Howard Group Conference
Opportunity Knocks III
October 2011

Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.



Biopharmaceutical company focused on bridging the treatment gap in cardiometabolic disorders through novel superior lipid management

Pipeline of

Omega-3 Phospholipid products

(from Neptune Krill Oil - NKO®)

Corporate Overview

- *Acasti Pharma founded 2008 – Listed 03/2011 (APO on TSX-V)*

Subsidiary of  **NEPTUNE**
TECHNOLOGIES & BIORESSOURCES

- *NKO® Krill based Omega-3 Phospholipid products focused on lipid management in CVD*
- *Exclusive licence from Neptune for Cardiovascular pharmaceutical application*
- *Full access to Neptune's manufacturing & intellectual property*
- *Strong and advantageous IP position*

Current treatment targets lipid control:

- *Lower total cholesterol and LDL-C*
- *Lower triglycerides*
- *Increase HDL-C*

Current treatment options and limitations:

- *Statins – lowers LDL-C*
- *Niacin – increases HDL-C*
- *Fibrates – lowers triglycerides*
- *Omega-3 – lowers triglycerides (increase or minimal impact on LDL-C)*

Cardiovascular disease lipid modification limitations

- *Statins reduce LDL but minimal positive impact on HDL and triglycerides (TG) while increasing the risk of diabetes*
- *Statin monotherapy does not eliminate CVD risks associated with high TG and low HDL (Carrie et al. Am. J. Cardiol., Sept 15, 2010)*
- *Unmet medical need for ↓TG; ↓LDL and ↑HDL - The perfect "lipid trifecta"*
- *Acasti Omega-3 Phospholipid is ideal with potential impact on ↓TG; ↓LDL ; potential enhancer of Statin therapy; potential use in Statin intolerant patients*

CaPre[®] - Competitive landscape

Company: (Product)	Status	Indication	Safety & Efficacy
Acasti: CaPre[®]	Initiating phase II in 2011	<ul style="list-style-type: none"> • Adjunct to diet • Patients with moderate - high TG levels (≥ 200 mg/dL) 	<ul style="list-style-type: none"> • TG decrease • LDL decrease • HDL increase
GSK: Lovaza[®]	On market	<ul style="list-style-type: none"> • Adjunct to diet • Patients with high TG levels (≥ 500 mg/dL) 	<ul style="list-style-type: none"> • TG decrease • LDL increase • HDL unaffected
Amarin: AMR101[®]	Phase III completed	<ul style="list-style-type: none"> • Adjunct to statin • Patients with high TG levels (≥ 200 mg/dL) 	<ul style="list-style-type: none"> • TG decrease • LDL unaffected • HDL unaffected

<i>Category</i>	<i>Description</i>
<i>Novel Phospholipid</i>	<i>Composition of Matter*</i> ≥ 2025
<i>Cardiovascular applications</i>	<i>Method of Use*</i> ≥ 2025
<i>Health applications</i>	<i>Composition and Use*</i> ≥ 2022
<i>Extraction applications</i>	<i>Process*</i> ≥ 2020
<i>Pharmaceutical applications</i>	<i>Composition and Use</i> ≥ 2030

*license from Neptune Technologies

Pipeline of Krill based Omega-3 Phospholipid products



**Prescription
Drug**

Dyslipidemia – Cardiometabolic Disorders



**Medical
Food**

Omega-3 Phospholipid Deficiency




**Over the
Counter**

Cardiovascular Disease Drug Potentiator



Prescription
Drug
Candidate



Highly purified Omega-3 Phospholipid NKO® Krill based product - (*Not just another Fish Oil*)



Initial Indication : Hypertriglyceridemia

Expected clinical benefits:

- Improved lipid management
- Anti-inflammation and anti-oxidant effects
- Improved glucose tolerance

CaPre[®] Product development




<i>Product</i>		<i>Nonclinical</i>	<i>Clinical</i>			<i>Launch</i>
			<i>Phase I</i>	<i>Phase II</i>	<i>Phase III</i>	
CaPre [®]	Canada					
	USA					

CaPre[®] - Regulatory Program

Straightforward clinical path to market approval

- Preclinical:** – *GLP toxicology studies initiated - to be complete 4/12*
- CMC** – *cGMP analytical methods*
– *Clinical supplies manufactured and released according to*
- cGMP** – *Stability studies according to ICH (21 CFR part 310)*
- Clinical** – *Canadian studies to be initiated Q4/11*
– *Pharmacokinetic study*
– *Open-label Dose escalation study*
– *Placebo controlled blind dose escalation*
– *US clinical strategy underway – IND 2012*

CaPre[®] precursor improves statin effect



Unpublished data



Indication : For the management of Omega-3 Phospholipid Deficiency

Medical Food distributed to the doctor's office





60-year-old female, referred for an abnormal lipid profile. On presentation, lipid profile showed:

TC = 236 HDL = 36 Trig = 395 LDL = 160

Simvastatin 40mg with a lipid profile 6 weeks later showing:

TC = 158 HDL = 25 Trig = 215 LDL = 90

Onemia 1gm was started. Six weeks later a lipid profile showed:

TC = 134(16%) HDL = 40 Trig = 178 (16%) LDL = 58 (35%)



38-year-old male, who was referred with a high trig level. Started on Fenofibrate 600mg a day. Lipid profile prior to the fibrate start was:

TC = 435 HDL = 29 Trig = 1250 LDL – not able to calculate

The patient was sent to a nutritionist, as well as started on the fibrate. He came in to my office for a consult 3 weeks later, with a lipid profile:

TC = 284 HDL = 55 Trig = 395 LDL = 150

The patient was started on Onemia 1gm per day. He returned 2 months later with a lipid profile of:

TC = 134(53%) HDL = 40 Trig = 178 (55%) LDL = 60 (60%)



60-year-old male, referred for dyslipidemia. Started a statin and fibrate, both of which he could not tolerate. Lipid profile showed:

TC = 198 HDL = 38 Trig = 190 LDL = 124

Onemia 1gm per day was started. A lipid profile 2 months later showed:

TC = 135(32%) HDL = 38 Trig = 100 (48%) LDL = 77 (38%)

Financial Overview

TSX – Venture Exchange • Symbol “APO”

- **Shares Outstanding:** 71,031,138
- **Shares Outstanding Fully diluted :** 80,165,332
- **Stock Price (Sept 15, 2011):** \$1.35
- **Implied Market Capitalization:** \$95,892,036
- **Cash on hand (Sept 15, 2011):** \$9,250,000

- **Analyst Coverage :**
 - **Joseph Pantginis, Roth Capital Partners**
 - **Robin Cornwell, Catalyst Research**

Acasti TSX listing: "APO"

Acasti Pharma Inc (TSX-V : V.APO)



As of Sept. 16th 2011

Corporate Objectives

- *Increase Acasti visibility in medical, pharmaceutical & financial markets*
- *Initiate and Complete Canadian clinical studies*
- *Prepare and Submit U.S. IND (H1-H2/2012)*
- *Initiate U.S. Clinical Trials (2012)*
- *Evaluate potential of U.S. exchange listing*

The Team

Management:

Henri Harland, BSc Act, MBA
Chief Executive Officer

Tina Sampalis, MD, PhD
President

Harlan W. Waksal, MD
Executive VP

Pierre Lemieux, PhD
Chief Operating Officer

Xavier Harland, BSc Act, CFA, FRM
Chief Financial Officer

Thank you!

